Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck USA (MSD) acquires Phase 2 blood cancer co - US$1.35B

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 12, 2022 12:15pm

152 Views

Post# 35166294

RE:Merck USA (MSD) acquires Phase 2 blood cancer co - US$1.35B

December 12, 2022 - Merck known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Imago Biosciences Inc. On Nov. 21, 2022, Merck announced that it had entered into a definitive agreement to acquire Imago.

https://www.biospace.com/article/releases/merck-begins-tender-offer-to-acquire-imago-biosciences-inc-/

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks